Vir Biotechnology (NASDAQ:VIR) EVP Mark Eisner Sells 1,616 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 1,616 shares of Vir Biotechnology stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total value of $15,400.48. Following the completion of the transaction, the executive vice president owned 155,913 shares in the company, valued at $1,485,850.89. This represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Mark Eisner also recently made the following trade(s):

• On Wednesday, February 25th, Mark Eisner sold 1,889 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.82, for a total value of $18,549.98.
• On Monday, February 23rd, Mark Eisner sold 2,089 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $15,563.05.

Vir Biotechnology Stock Performance

VIR traded down $0.23 on Friday, hitting $9.09. The company had a trading volume of 719,863 shares, compared to its average volume of 3,674,494. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -2.89 and a beta of 1.69. The stock has a fifty day moving average price of $6.95 and a 200-day moving average price of $6.04. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The business had revenue of $64.07 million for the quarter, compared to analysts’ expectations of $19.91 million. During the same period last year, the business earned ($0.76) EPS. The company’s revenue was up 417.8% compared to the same quarter last year. Analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration with Vir on the prostate‑cancer asset (VIR‑5500) includes up‑front/near‑term payments and up to about $1.7 billion in contingent milestones — a material de‑risking and commercialization path for a late‑stage asset. Read More.
• Positive Sentiment: Quarterly results beat expectations: Q4 revenue (~$64M) and EPS topped consensus, signaling improving commercial traction and supporting higher analyst enthusiasm. Read More.
• Positive Sentiment: Analyst upgrades and target increases followed the news (Needham raised its target to $18), boosting upside sentiment despite current volatility. Read More.
• Neutral Sentiment: Management will present at investor conferences in early March (TD Cowen, Leerink), which can provide clarity but are not a fundamental catalyst by themselves. Read More.
• Neutral Sentiment: Comparative coverage and peer analyses are increasing visibility and trading volume (e.g., head‑to‑head pieces with peers), but they don’t change Vir’s underlying cash flow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross proceeds). The discounted placement strengthens the balance sheet but is dilutive and increases near‑term share supply, pressuring the stock. Read More.
• Negative Sentiment: Coverage noted the discounted offering as the proximate cause of the post‑rally pullback/tumble, amplifying short‑term selling. Read More.
• Negative Sentiment: Significant insider selling was disclosed (multiple officers and a director reported sales last week), which—combined with the offering—added visible supply and negative sentiment. Read More.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently modified their holdings of VIR. ARCH Venture Management LLC purchased a new position in Vir Biotechnology during the second quarter valued at approximately $65,100,000. Aberdeen Group plc boosted its position in Vir Biotechnology by 51.6% in the 3rd quarter. Aberdeen Group plc now owns 1,526,265 shares of the company’s stock worth $8,715,000 after purchasing an additional 519,374 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in shares of Vir Biotechnology by 812.7% during the 2nd quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company’s stock worth $2,938,000 after purchasing an additional 519,107 shares during the period. Corton Capital Inc. purchased a new position in shares of Vir Biotechnology during the 2nd quarter valued at approximately $114,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Vir Biotechnology during the 2nd quarter valued at approximately $63,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on VIR. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price target on shares of Vir Biotechnology in a research report on Thursday. Needham & Company LLC upped their price objective on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Evercore reiterated an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a research note on Tuesday. Barclays boosted their target price on shares of Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a report on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.89.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.